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Evoked catecholamine s cretion from cultured bovine adrenal medullary cells is inhibited by commercially 
available botulinum toxins - types A, B and D (104106 MLD/ml.of culture medium). Basal secretion is 
also inhibited. The catecholamine content of such toxin-treated cells is larger than that of control cells and 
may in part be a result of the inhibition of basal release. The onset of action of botulinum toxin types A 
and D can be neutralised by their respective antisera. Concentrations of botulinum toxins A, B or D that 
inhibit secretion leave unaffected the 45Ca2+ influxes normally associated with secretion. These data provide 
further evidence to support he idea [(1985) Nature 317, 719-721] that botulinum toxins block secretion 
by acting downstream ofthe Ca z+ transient at or near the site of exocytosis. 
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1. INTRODUCTION 
Transmitter release from peripheral cholinergic 
nerve endings is blocked by botulinum toxins, 
leading to muscular weakness and paralysis [2-4]. 
Little is known though of the mechanism by which 
these toxins act and this is perhaps in part due to 
the lack of a suitable in vitro cholinergic prepara- 
tion. One type of botulinum toxin however (type 
D) has also been reported to block catecholamine 
secretion from cultured bovine adrenal medullary 
cells [1]. The value of this adrenergic preparation 
to elucidate the mechanism of cholinergic block is 
not certain though because inhibition of 
catecholamine s cretion was reported to occur only 
with type D toxin, whereas botulinum toxin types 
A and B are, in the main, equally effective at 
blocking in vivo cholinergic synapses [2,3]. This 
difference could arise because the chromaffin cell 
has receptors ensitive only to toxin type D, or that 
only type D is effective intracellularly, or simply 
that the concentrations of the other toxins used 
were not high enough. There was also the remote 
possibility that the inhibitory effect seen with the 
sample of D toxin was not in fact due to botulinum 
toxin at all but rather to some contaminant. This 
paper describes a series of experiments hat set out 
to reexamine the effects of a range of commercially 
available botulinum toxins on both basal and 
evoked catecholamine secretion. The experiments 
show that types A, B and D are equally effective in 
blocking catecholamine s cretion, and in a manner 
that is entirely consistent with the earlier report 
that these toxins may inhibit secretion by acting 
downstream of the Ca 2+ transient and at or near 
the site of exocytosis. 
2. MATERIALS AND METHODS 
Cells were isolated, cultured, incubated with 
toxins and challenged with carbamylcholine as 
described before [1,5,6], the only difference being 
that the cells were cultured in Dulbecco's modified 
Eagle's Medium containing 10% fetal calf serum, 
100 U.ml - I  penicillin G and 5/zM cytosine 
arabinoside. Botulinum toxin types A, B, C and D 
were obtained from Wako Pure Chemical In- 
dustries Ltd, Japan. Toxins were diluted for use in- 
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to glycerol phosphate buffer, pH 6.0, and 50,ul 
added to each 1 ml culture well. The pote~:cies of 
The toxins were calibrated in terms of mouse lethal 
closes (MLD), Wistar mice (average weight 23 g) 
being used. Type A, B, C, D and E botulinum an- 
titoxin sera were used in aliquots of 50/d (each 
containing 5 international units of antitoxin). The 
antitoxins were mixed with 50/zl toxin for 3 rain 
before the mixtures were added to 1 ml culture 
medium. 45Ca influx experiments .were performed 
as described elsewhere [1]. The effect of toxin on 
basal release was determined by first incubating 
over 3 days the cultured cells with botulinum toxin 
together with 100/~M ascorbate and 1.4/~Ci of 
[3H]noradrenaline per ml of culture medium 
(equivalent to 3 x 10 -8 M noradrenaline). Addi- 
tional [3Hlnoradrenaline and ascorbate (3 x 
10 -8 M and 100/~M, respectively) were added after 
24 and 48 h. Cells were then washed 7 times in 
culture medium at 37°C over a 5 rain period and 
incubated with 0.5 ml culture medium per culture 
well over a 5 h period at 37°C. The 0.5 ml of 
culture medium was changed every 30 min, and the 
amount of label released into these 0.5 ml samples 
measured. At the end of the 5 h period the cultured 
cells were challenged at 37°C with culture medium 
containing carbamylcholine, and the amounts of 
3H label and cold catecholamine r leased over a 
30 min period measured. Toxin-treated cultured 
cells were also incubated for a short 20 min period 
with [3Hlnoradrenaline and ascorbate before being 
rapidly washed and challenged with car- 
bamylcholine as before. 
3. RESULTS 
The measured potencies of Wako toxin types A, 
B and D agreed well with those reported by the 
company, i.e. 2 x 10 7 MLD per mg of type A or 
type B proteins, and  2 × 10 s MLD per mg of type 
D protein. Type C toxin however was found to be 
over 2 orders of magnitude less potent than that 
measured by the company 1 month earlier. It is 
possible therefore that the C toxin decomposed 
during this one month period. Some aliquots of  B 
toxin also appeared unstable and lost their poten- 
cy, but this was not so marked as with the C toxin. 
The highest concentrations of toxins used in the ex- 
periments with adrenal cells were 106 , 10 6 and 10 7 
t.ETTERS October 1986 
MLD, respectively, for type A, B and D toxins, 
and 5 × 10 2 MLD for type C toxin. 
Botulinum toxin types A, B and D inhibited 
evoked catecholamine secretion in a dose- 
dependent manner (figs 1 and 2). Fig.1 shows that 
incubation with l -5 /zg /ml  of the toxins, cor, 
responding to 2 x 104-2 × 105 MLD, for 6 days, 
inhibited evoked secretion by 50%. The potency is 
time dependent as in the same experiment he 
amounts of toxin needed to give half-maximal: in, 
hibition after only 3 days of incubation were ap, 
prox. 5 times the amounts needed for the 6 day 
incubation. Botulinum toxin type C, when used a t  
its highest concentratioS ffor 6 days, also had a 
small inhibitory effect on evoked secretion (fig.l), 
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Fig.1. Inhibition of evoked catecholamine s cretion by 
botulinum toxins. Cells were incubated with the various 
quantities of toxin shown for 6 days before being washed 
with physiological saline containing 3 mM Ca z÷, and 
challenged with 5 x 10 -4 M carbamylcholine for 15 min 
at 20°C. Secretion, closed symbols; total catecholamine 
in the culture wells, open symbols. Data points are 
means of 3 determinations (error bars = SE). (a) 
Botulinum toxin types A (o,o) and B (*,~7-~). (b) 
Botulinum toxin types C (o,o), and D (*, o). • 
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Fig.2. Inhibition of basal and evoked release by 
botulinum toxin type D. Release is shown normalised to 
that occurring in the absence of the toxin, the data 
points being the means of 4 determinations (error bars = 
SE). (e) Basal release of 3H measured over 5 h from 
unstimulated cells that had been preincubated with 
toxins and [3H]noradrenaline for 3 days. Release in the 
absence of the toxin was 1.5°70 of the cellular content per 
hour; (o) evoked release of 3H from the same cells over 
30 min at 37°C by 5 × 10-4M carbamylcholine, the 
evoked release in the absence of toxin was 6°70; (o) 
evoked release as-above but from cells preincubated with 
[3H]noradrenaline for only 20 min prior to being 
challenged to secrete, the amount released in the absence 
of the toxin was 11 070. 
The botulinum toxins that are effective at block- 
ing secretion also increase the total catecholamine 
content of the cultured cells, the increase occurring 
over the same toxin concentration range and time 
course as inhibition of secretion. Fig. lb shows for 
example that after 6 days of incubation with type 
D toxin the evoked secretion is inhibited by over 
90% and the catecholamine content of the cells is 
double that of control cells. Whilst a component of 
this increase might be attributed to an increase in 
catecholamine synthesis, another explanation 
could be that the basal rate of  secretion is also in- 
hibited by botulinum toxins. Measurement of 
basal catecholamine r lease over a period of hours 
was unsuccessful using the standard fluorimetric 
trihydroxyindole assay [5,7] because of the small 
amounts of catecholamine secreted and the in- 
stability (oxidation) of the amine at pH 7.4 and 
37°C. Measurements of basal release from cells 
preloaded with [3H]noradrenaline proved possible 
however. Fig.2 shows the basal release of 3H over 
a 5 h period. The data clearly show that cells in- 
cubated with botulinum toxin type D release less 
label than do control ceils, the dose dependence of  
the toxin being very similar to that for inhibition of 
evoked release of 3H label or of endogenous 
catecholamine. The extent of the inhibition 
however seems to be somewhat different, evoked 
release being inhibited by over 90% whereas basal 
release from the same set of cells is only inhibited 
a little over 50%. The rate of basal release de- 
creased from 1.5%/h (SE 0.25%/h, 4 determina- 
tions) for control cells, to 0.69%/h (SE 0.05%/h, 
4 determinations) for toxin-treated cells. 
The inhibition of evoked and basal secretion 
could be interpreted not only as a reduction in the 
extent of exocytosis but also, during the days of 
toxin treatment, as a slow redistribution of 
catecholamine within the cell into compartments 
that are not immediately associated with the 
secretory process. The data of fig.2 however show 
that the toxin dose-dependence for inhibition of 
evoked release is very similar for cells exposed to 
[3H]noradrenaline either for 3 days or for only 
20 min before being challenged, with a 
secretagogue. Such data showing that the potency 
of the toxin is independent of the time that the 
secretory product is in the cell give no support o 
the idea of a slow redistribution of secretory 
product away from granules undergoing ex- 
ocytosis. 
Even though very high concentrations of the 
toxins are necessary to block catecholamine s cre- 
tion, the cause of the block is almost certainly by 
action of the botulinum toxins, rather than by 
some foreign contaminant, as the potency of the 
toxins is lost when preincubated with botulinum 
toxin antisera prepared independently. Fig.3 shows 
that botulinum toxin type A potency is removed by 
preincubating the toxin with anti-A toxin an- 
tiserum, and that of type D toxin by preincubating 
with either types C or D antisera; These latter 
results are consistent with reported C and D type 
toxin-antitoxin crossreactivity [8]. 
So far, no conditions have been found to reverse 
the botulinum induced inhibitory effect. In one ex- 
periment for example, secretion was inhibited by 
89o-/0 after 4 days incubation with 10 6 MLD/ml  of 
botulinum toxin type D. Repeated washing and in- 
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Fig.3. Toxin-antitoxin eutralisation. 15/zg of'iype A 
and D toxins were incubated with 5 units of antitoxin for 
3 min before being added to 1 ml cell cultures. After 3 
days the cells were washed and challenged with 5 × 
l0 -4 M carbamylcholine for 15 min at 20°C. Data are 
means of 3 determinations (error bars = SE). (a) No 
toxin usedi (b) botulinum toxin type A; (c) botulinum 
toxin type D. 
cubation with an excess amount (5 units) of anti-D- 
toxin for a further 14 days was not sufficient for 
the cells to recover, the secretory response still be- 
ing depressed by 72°7o compared with control cells 
of the same age not initially treated with toxin. 
There is strong evidence to suggest that a rise in in- 
tracellular Ca 2÷ triggers catecholamine secretion, 
and that such a rise is brought about by a Ca 2÷ in- 
flux into the cells in response to depolarising 
agonists [9-11]. Fig.4 shows that this Ca 2÷ influx 
normally associated with secretion remains 
unaltered in cells treated with botulinum toxins A, 
B and D, whereas ecretion from the same cells is 
inhibited. 
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Fig.4. The effect of botulinum toxins on 45Ca influx. 
Cells were cultured at 1.5 × 106 cells per ml for 3 days 
with 15/zg per ml of botulinum toxin types A, B and D, 
before being challenged with 5 x 104 M carbamylcholine 
for 12 rain. The extracellular fluid was removed, the 
plates washed 5 times over 3 rain with ice-cold 
physiological saline containing 0.5% bovine serum 
albumin and the 45Ca associated with the cells 
determined. The second bar of each pair corresponds to
measurements made on stimulated cells. The data are 
means of 3 determinations (error bars =gSE). (Open 
bars) Catecholamine in the extracellular f~fiid; (closed 
bars )  45Ca associated with the same cells. 
4. DISCUSSION 
In an earlier paper [I] it was reported that of the 
toxins tested only botulinum toxin type D inhibited 
evoked catecholamine secretion from bovine 
adrenal medullary cells. The results presented here 
not , o.nly support this earlier finding that 
botulinum toxin type D inhibits catecholamine 
secretion from bovine chromaffimcells, but in ad- 
dition show that type A and B botUlinum toxins, 
when used in the same concentration rangeas type 
D toxin, also inhibit evoked release. Bot.ulinum 
toxin also inhibits basal release from chromaffin 
cells and this can account for the rise in cellular 
catecholamine that seems to be associated with 
toxin-treated cells. The data here are evidence that 
the botulinum toxins that inhibit acetylcholine 
release at the mouse neuromuscular junction-also 
inhibit catecholamine secretion from bovine 
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chromaffin cells in vitro. Furthermore the data are 
entirely consistent with the earlier proposal [1] for 
the mechanism of action of botulinum toxin on 
adrenal cells, i.e. by the toxin acting downstream 
of the Ca 2+ transient possibly at or near the site of 
exocytosis. The amount of toxin necessary to in- 
hibit catecholamine secretion from this in vitro 
preparation however is 4-5  orders of magnitude 
greater than that needed to block acetylcholine 
release in vivo. If  botulinum toxins act from within 
the cell [2-4], then it is unclear, at the moment, 
whether this difference in potency is because of a 
difference in the penetration i to the cytosol of the 
two preparations, or whether it is because of a dif- 
ference in the potency of the toxins once inside. If  
it is simply the case of a difference in penetration 
then it may be possible to increase the sensitivity of 
the chromaffin cell to the toxins by altering the 
surface properties of the cell [12], or to bypass the 
plasma membrane altogether by introducing small 
amounts of toxin directly into the cytosol by either 
microinjection, endocytosis, or by making use of 
the ' leaky' cell technique [13,14]. 
In summary, it looks very likely that the 
botulinum toxins inhibit secretion by acting at or 
near the site of exocytosis. 
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